AXSM
Axsome Therapeutics Inc
NASDAQ: AXSM · HEALTHCARE · BIOTECHNOLOGY
$183.95
-0.57% today
Updated 2026-04-29
Market cap
$9.46B
P/E ratio
—
P/S ratio
14.82x
EPS (TTM)
$-3.68
Dividend yield
—
52W range
$96 – $193
Volume
0.6M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A4.0
Quality
C2.0
Profitability
F6.7
Valuation
B4/9
Piotroski F-Score
Moderate
-2.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$223.90
+21.72%
12-Month target
—
—
Intrinsic (DCF)
$383.96
Margin of safety
+51.50%
3 Strong Buy17 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 65.00% QoQ
+ 51.50% below intrinsic value
Risks
- Altman Z -2.07 — distress zone
- Thin margins at -28.70%
- Negative free cash flow $-18.72M
- Debt/equity 2.96x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $50.04M | $270.60M | $385.69M | $638.50M | $638.50M |
| Net income | $-187.13M | $-239.24M | $-287.22M | $-183.17M | $-28.56M |
| EPS | — | — | — | — | $-3.68 |
| Free cash flow | $-117.21M | $-145.66M | $-128.68M | $-93.89M | $-18.72M |
| Profit margin | -373.99% | -88.41% | -74.47% | -28.69% | -28.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-26 | TABUTEAU, HERRIOT | Buy | 54,623 | — |
| 2026-02-26 | PIZZIE, NICK | Buy | 18,570 | — |
| 2026-02-26 | MURDOCK, HUNTER R. | Buy | 16,385 | — |
Peer comparison
Smart narrative
Axsome Therapeutics Inc trades at $183.95. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.07, it sits in the distress. TTM revenue stands at $638.50M. with profit margins at -28.70%. Our DCF model estimates intrinsic value at $383.96.
Frequently asked questions
What is Axsome Therapeutics Inc's stock price?
Axsome Therapeutics Inc (AXSM) trades at $183.95.
Is Axsome Therapeutics Inc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell). DCF value $383.96.
What is the price target of Axsome Therapeutics Inc (AXSM)?
The analyst target price is $223.90, representing +21.7% upside from the current price of $183.95.
What is the intrinsic value of Axsome Therapeutics Inc (AXSM)?
Based on our DCF model, intrinsic value is $383.96, a +51.5% margin of safety versus $183.95.
What is Axsome Therapeutics Inc's revenue?
TTM revenue is $638.50M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.07 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio14.82x
ROE-252.10%
Beta0.47
50D MA$170.84
200D MA$146.60
Shares out0.05B
Float0.04B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—